Skip to navigation Site map About Us Careers Contact DISCOVaerie™ Live! SEARCH ABOUT US We are committed to building a major ophthalmic pharmaceutical company. Our pathway to global leadership in eye care is based on continuous scientific innovation, world-class clinical development, and company-wide operational excellence in the pursuit of novel treatments for diseases of the eye with significant unmet need. Aerie Corporate Highlights Aerie Pharmaceuticals, Inc. is a publicly-traded company (NASDAQ: AERI) Offices HQ – Durham, NC Irvine, CA Bedminster, NJ Dublin, Ireland Tokyo, Japan Henley-on-Thames, United Kingdom Manufacturing Facilities Athlone, Ireland (cGMP sterile fill plant) Durham, NC (cGMP PRINT® implant production laboratory) Employees: Approximately 400 Aerie Product Portfolio Rhopressa® (netarsudil ophthalmic solution) 0.02% U.S. FDA approval – December 2017 U.S. commercial launch – April 2018 Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% U.S. FDA approval – March 2019 U.S. commercial launch – May 2019 Rhokiinsa® (netarsudil 200 micrograms/ml eye drops solution) EU marketing authorisation – November 2019 Roclanda® (netarsudil 200 micrograms/ml and latanoprost 50 micrograms/ml eye drops) EU marketing authorisation – January 2021 Mercury 3 90-day topline results announced Marketing authorisation for Great Britain – April 2021 Pipeline Activities Globalization plan for netarsudil franchise under way Europe Commercialization planning underway Japan Phase 2 study of netarsudil completed Exclusive collaboration and license agreement completed with Santen for Japan and 8 other Asian nations. Positive Phase 3 topline results reported October 2021 Dry Eye Disease program AR-15512 (TRPM8 receptor agonist eye drop) Phase 2b trial (COMET-1) results reported September 2021 Retinal Disease program AR-1105 (dexamethasone sustained release implant) Positive Phase 2 topline results reported July 2020 Phase 3 planning underway in the U.S. and EU AR-13503 (Rho kinase/Protein kinase C inhibitor sustained release implant) First-in-human clinical study ongoing AR-14034 (Pan-VEGF receptor inhibitor sustained release implant) IND-enabling pre-clinical studies underway Ocular Inflammation program AR-6121 (Rho kinase inhibitor-linked-steroid – “ROCK’Ster”) IND-enabling pre-clinical studies underway Small-molecule multi-kinase inhibitors in discovery and pre-clinical development for other ophthalmic diseases and conditions Proprietary library of more than 4,000 molecules PRODUCTS Overview Rhopressa® Rocklatan® DISCOVaerie™ Live! R&D Pipeline Glaucoma Ocular Surface Disease - AR-15512 Retinal Disease - AR-1105 Implant - AR-13503 SR Implant - AR-14034 SR Implant Clinical Trials Research Bibliography Investigator Initiated Research Medical Affairs INVESTORS FAQs News & Presentations Stock Information Reports & Filings Corporate Governance Our Leadership Our Board of Directors Contact Us ABOUT US Our Scientific Heritage Aerie At-a-Glance Our Leadership Our Board of Directors Our ESG Commitment CAREERS CONTACT General Inquiries Corporate Headquarters 4301 Emperor Blvd Suite 400 Durham, NC 27703 Tel. +1 919-237-5300 AERIE PHARMACEUTICALS, INC. ©2021 All Rights Reserved. This site intended for U.S. audiences only.